310 related articles for article (PubMed ID: 28359391)
1. Study types and reliability of Real World Evidence compared with experimental evidence used in Polish reimbursement decision-making processes.
Wilk N; Wierzbicka N; Skrzekowska-Baran I; Moćko P; Tomassy J; Kloc K
Public Health; 2017 Apr; 145():51-58. PubMed ID: 28359391
[TBL] [Abstract][Full Text] [Related]
2. Relating Health Technology Assessment recommendations and reimbursement decisions in Poland in years 2012-2014, a retrospective analysis.
Kawalec P; Malinowski KP
Health Policy; 2016 Nov; 120(11):1240-1248. PubMed ID: 28029415
[TBL] [Abstract][Full Text] [Related]
3. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
Malinowski KP; Kawalec P; Trąbka W
Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
[TBL] [Abstract][Full Text] [Related]
4. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND.
Lipska I; McAuslane N; Leufkens H; Hövels A
Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170
[TBL] [Abstract][Full Text] [Related]
5. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015.
Kawalec P; Malinowski KP; Trąbka W
Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400
[TBL] [Abstract][Full Text] [Related]
6. Is Real-World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Hurwitz JT; Brown M; Graff JS; Peters L; Malone DC
J Manag Care Spec Pharm; 2020 Dec; 26(12):1604-1611. PubMed ID: 33251991
[TBL] [Abstract][Full Text] [Related]
7. Reimbursement of biosimilars in Poland: is there a link to health technology assessment?
Neumann D; Jabłecka A
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654
[TBL] [Abstract][Full Text] [Related]
8. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
9. Use of real-world evidence for healthcare decision-making in the Middle East: practical considerations and future directions.
Akhras KS; Alsheikh-Ali AA; Kabbani S
Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):245-250. PubMed ID: 30626231
[TBL] [Abstract][Full Text] [Related]
10. Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact.
Brown JP; Douglas IJ; Hanif S; Thwaites RMA; Bate A
Value Health; 2021 Sep; 24(9):1241-1244. PubMed ID: 34452702
[TBL] [Abstract][Full Text] [Related]
11. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?
Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS
Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840
[TBL] [Abstract][Full Text] [Related]
12. Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions.
Deverka PA; Douglas MP; Phillips KA
Value Health; 2020 May; 23(5):540-550. PubMed ID: 32389218
[TBL] [Abstract][Full Text] [Related]
13. Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance.
Jaksa A; Wu J; Jónsson P; Eichler HG; Vititoe S; Gatto NM
J Comp Eff Res; 2021 Jun; 10(9):711-731. PubMed ID: 33928789
[TBL] [Abstract][Full Text] [Related]
14. The use of real-world evidence in ICER's scoping process and clinical evidence assessments.
Jiao B; Veenstra DL; Lee W; Carlson JJ; Devine B
J Manag Care Spec Pharm; 2020 Dec; 26(12):1590-1595. PubMed ID: 33251999
[No Abstract] [Full Text] [Related]
15. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
16. Payer perceptions of the use of real-world evidence in oncology-based decision making.
Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
[No Abstract] [Full Text] [Related]
17. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
[TBL] [Abstract][Full Text] [Related]
18. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
F1000Res; 2018; 7():111. PubMed ID: 30026923
[TBL] [Abstract][Full Text] [Related]
19. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations.
Briere JB; Bowrin K; Taieb V; Millier A; Toumi M; Coleman C
Curr Med Res Opin; 2018 Dec; 34(12):2125-2130. PubMed ID: 30217138
[TBL] [Abstract][Full Text] [Related]
20. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
